PKM2 Inhibitor (Compound 3k): Selective Disruption of Cancer Cell Glycolysis

Executive Summary: PKM2 inhibitor (compound 3k) is a potent, selective inhibitor of pyruvate kinase M2 (PKM2), a key enzyme in the glycolytic pathway predominantly expressed in tumor cells. It displays an IC₅₀ of 2.95 μM against PKM2 and exerts nanomolar antiproliferative activity in cell lines such as HCT116 (0.18 μM), Hela (0.29 μM), and H1299 (1.56 μM), with greater selectivity for cancer over normal cells (APExBIO, product page). Oral administration in SK-OV-3 xenograft mice at 5 mg/kg every two days for 31 days reduced tumor volume without significant toxicity (APExBIO). The compound is instrumental for interrogating PKM2-dependent metabolic reprogramming in both oncology and inflammation settings (Wu et al., 2025, DOI). Its robust selectivity and in vivo tolerability support applications in preclinical cancer metabolism and immune modulation research.

Biological Rationale

Pyruvate kinase M2 (PKM2) is a rate-limiting enzyme in glycolysis, catalyzing the conversion of phosphoenolpyruvate to pyruvate. PKM2 is preferentially expressed in proliferating cells, including many tumor types, and is essential for maintaining the high glycolytic flux characteristic of the Warburg effect (Wu et al., 2025). Cancer cells rely on aerobic glycolysis for energy production and anabolic growth, making PKM2 an attractive therapeutic target. Inhibition of PKM2 disrupts this metabolic program, leading to energy depletion, altered redox balance, and impaired biomass synthesis in cancer cells. PKM2 also regulates gene transcription and cellular phenotype, influencing both cancer progression and immune cell polarization (Rewiring Cancer and Immune Metabolism). The selective targeting of PKM2 thus offers dual benefits: direct antiproliferative effects on tumor cells and modulation of inflammatory responses in the tumor microenvironment and diseases such as severe acute pancreatitis.

Mechanism of Action of PKM2 inhibitor (compound 3k)

PKM2 inhibitor (compound 3k) is a small-molecule inhibitor with a molecular weight of 345.48 and a chemical formula of C₁₈H₁₉NO₂S₂ (APExBIO product page). It binds selectively to PKM2, inhibiting its enzymatic activity with an IC₅₀ of 2.95 μM. This inhibition reduces the conversion of phosphoenolpyruvate to pyruvate, lowering cellular ATP and lactate production—key readouts of aerobic glycolysis disruption. In cancer cells overexpressing PKM2, this leads to a pronounced reduction in proliferation and survival, especially under high-glucose, hypoxic, or growth-factor-rich conditions. Compound 3k's selectivity over PKM1 and other pyruvate kinase isoforms reduces off-target effects in non-tumor tissues (Selective Disruption of Cancer Glycolysis). In immune cells, particularly macrophages, PKM2 inhibition shifts polarization from pro-inflammatory (M1) to anti-inflammatory (M2) phenotypes, which can modulate inflammation in diseases such as severe acute pancreatitis (Wu et al., 2025).

Evidence & Benchmarks

• Demonstrates an IC₅₀ of 2.95 μM against recombinant PKM2 enzyme in vitro (APExBIO, product page).
• Exhibits antiproliferative activity in cancer cell lines: HCT116 (IC₅₀ = 0.18 μM), Hela (0.29 μM), H1299 (1.56 μM); lower toxicity observed in BEAS-2B normal cells (APExBIO).
• Significantly reduces tumor volume and weight in SK-OV-3 xenograft-bearing BALB/c nude mice at 5 mg/kg oral dosing every 2 days for 31 days, with no major organ toxicity or animal weight loss (APExBIO).
• PKM2 inhibition reverses the protective effect of USP7 knockdown in severe acute pancreatitis mouse models, confirming PKM2’s role in metabolic reprogramming and inflammation (Wu et al., 2025).
• PKM2 inhibitor (compound 3k) disrupts PKM2-dependent glycolytic flux, as measured by reduced extracellular acidification rate (ECAR) in Seahorse assays (Wu et al., 2025).

This article extends the discussion in Selective Disruption of Cancer Glycolysis by incorporating new in vivo efficacy benchmarks and highlighting the dual oncology and immunometabolic applications of compound 3k.

It also clarifies mechanistic aspects covered in Rewiring Cancer and Immune Metabolism by detailing the direct evidence for PKM2-dependent immunometabolic reprogramming.

Applications, Limits & Misconceptions

Primary Applications:

• Preclinical research on cancer cell metabolism inhibition and tumor growth suppression (APExBIO).
• Studies of PKM2-mediated immune cell polarization and inflammation modulation, including acute pancreatitis (Wu et al., 2025).
• Assessment of glycolytic pathway inhibition and autophagic cell death induction in tumor models.
• Screening for tumor-selective PKM2 targeting and combination strategies with existing chemotherapeutics.

Common Pitfalls or Misconceptions

• Compound 3k is not active against PKM1 or non-glycolytic isoforms; its effects are primarily limited to PKM2-overexpressing cells (see dossier).
• It is not a pan-cancer agent; efficacy depends on PKM2 expression levels—tumors with low PKM2 may show minimal response.
• The compound is insoluble in ethanol and water; DMSO is required for stock solution preparation, and solutions are not recommended for long-term storage (APExBIO).
• Data on human clinical safety are lacking; current efficacy and safety profiles are limited to cell and animal models.
• It is not intended for direct use as a therapeutic in humans outside research settings.

Workflow Integration & Parameters

PKM2 inhibitor (compound 3k) is provided as a solid and should be stored at -20°C. It is soluble at ≥34.5 mg/mL in DMSO with gentle warming. For in vitro assays, recommended working concentrations range from 0.1 μM to 10 μM, depending on cell line sensitivity and PKM2 expression levels. In vivo, an efficacious dose in mouse xenograft models is 5 mg/kg by oral administration every two days, but dosing may require optimization based on tumor model and route (APExBIO). Researchers should confirm protein expression and glycolytic phenotype in target cells prior to use. For studies of immunometabolic modulation, validated protocols for macrophage polarization and inflammatory readouts are recommended (Wu et al., 2025).

Conclusion & Outlook

PKM2 inhibitor (compound 3k, B8217, APExBIO) represents a validated, selective chemical tool for dissecting PKM2-dependent cancer and immune cell metabolism. Its nanomolar potency, tumor-selective cytotoxicity, and in vivo activity in ovarian cancer models underscore its value in preclinical research. The compound is especially suited to studies on aerobic glycolysis disruption, autophagic cell death induction, and immunometabolic reprogramming. Ongoing research is needed to further elucidate its therapeutic potential and to translate findings into clinical applications. For a comprehensive overview of its current and emerging uses, see the PKM2 inhibitor (compound 3k) product details and recent literature (Wu et al., 2025).